.png){kind=icon}
.png){kind=icon}
Return
TAV-in-TAV-in-TAV after treated endocarditis: procedural strategy, imaging planning and 1-year outcome
.png){kind=icon}
PRE
AI
M
A
T
P
Z
T
G
K
DOI：10.1136/bcr-2025-269921.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Given the diverse technical challenges associated with transcatheter valve-in-transcatheter valve procedures, the treatment strategy for each clinical case must be tailored to the individual patient. We present the case of a man in his late 70s with a complex clinical history, including two prior transcatheter aortic valve implantation (TAVI) procedures and infective endocarditis, who later developed severe degeneration of the aortic prosthesis requiring a third transcatheter intervention. Initially treated with a Lotus valve in 2014, the patient underwent a TAV-in-TAV with an Evolut prosthesis in 2022, followed by endocarditis-related degeneration and severe restenosis. In 2024, a third prosthetic valve (Acurate neo2) was implanted using the TAV-in-TAV-in-TAV technique. With expanding indications for TAVI and increasing longevity among treated patients, complex multi-prosthesis interventions may become more frequent, highlighting the need for improved procedural planning, imaging strategies and long-term surveillance. At 1-year follow-up, the patient remains asymptomatic with preserved valve function. This case illustrates the feasibility of a third TAVI after treated prosthetic valve endocarditis, supported by CT-guided procedural planning and 1-year follow-up, which remains scarcely reported in the literature.Summary Given the diverse technical challenges associated with transcatheter valve-in-transcatheter valve procedures, the treatment strategy for each clinical case must be tailored to the individual patient. We present the case of a man in his late 70s with a complex clinical history, including two prior transcatheter aortic valve implantation (TAVI) procedures and infective endocarditis, who later developed severe degeneration of the aortic prosthesis requiring a third transcatheter intervention. Initially treated with a Lotus valve in 2014, the patient underwent a TAV-in-TAV with an Evolut prosthesis in 2022, followed by endocarditis-related degeneration and severe restenosis. In 2024, a third prosthetic valve (Acurate neo2) was implanted using the TAV-in-TAV-in-TAV technique. With expanding indications for TAVI and increasing longevity among treated patients, complex multi-prosthesis interventions may become more frequent, highlighting the need for improved procedural planning, imaging strategies and long-term surveillance. At 1-year follow-up, the patient remains asymptomatic with preserved valve function. This case illustrates the feasibility of a third TAVI after treated prosthetic valve endocarditis, supported by CT-guided procedural planning and 1-year follow-up, which remains scarcely reported in the literature.Summary Given the diverse technical challenges associated with transcatheter valve-in-transcatheter valve procedures, the treatment strategy for each clinical case must be tailored to the individual patient. We present the case of a man in his late 70s with a complex clinical history, including two prior transcatheter aortic valve implantation (TAVI) procedures and infective endocarditis, who later developed severe degeneration of the aortic prosthesis requiring a third transcatheter intervention. Initially treated with a Lotus valve in 2014, the patient underwent a TAV-in-TAV with an Evolut prosthesis in 2022, followed by endocarditis-related degeneration and severe restenosis. In 2024, a third prosthetic valve (Acurate neo2) was implanted using the TAV-in-TAV-in-TAV technique. With expanding indications for TAVI and increasing longevity among treated patients, complex multi-prosthesis interventions may become more frequent, highlighting the need for improved procedural planning, imaging strategies and long-term surveillance. At 1-year follow-up, the patient remains asymptomatic with preserved valve function. This case illustrates the feasibility of a third TAVI after treated prosthetic valve endocarditis, supported by CT-guided procedural planning and 1-year follow-up, which remains scarcely reported in the literature.Summary Given the diverse technical challenges associated with transcatheter valve-in-transcatheter valve procedures, the treatment strategy for each clinical case must be tailored to the individual patient. We present the case of a man in his late 70s with a complex clinical history, including two prior transcatheter aortic valve implantation (TAVI) procedures and infective endocarditis, who later developed severe degeneration of the aortic prosthesis requiring a third transcatheter intervention. Initially treated with a Lotus valve in 2014, the patient underwent a TAV-in-TAV with an Evolut prosthesis in 2022, followed by endocarditis-related degeneration and severe restenosis. In 2024, a third prosthetic valve (Acurate neo2) was implanted using the TAV-in-TAV-in-TAV technique. With expanding indications for TAVI and increasing longevity among treated patients, complex multi-prosthesis interventions may become more frequent, highlighting the need for improved procedural planning, imaging strategies and long-term surveillance. At 1-year follow-up, the patient remains asymptomatic with preserved valve function. This case illustrates the feasibility of a third TAVI after treated prosthetic valve endocarditis, supported by CT-guided procedural planning and 1-year follow-up, which remains scarcely reported in the literature.Summary Given the diverse technical challenges associated with transcatheter valve-in-transcatheter valve procedures, the treatment strategy for each clinical case must be tailored to the individual patient. We present the case of a man in his late 70s with a complex clinical history, including two prior transcatheter aortic valve implantation (TAVI) procedures and infective endocarditis, who later developed severe degeneration of the aortic prosthesis requiring a third transcatheter intervention. Initially treated with a Lotus valve in 2014, the patient underwent a TAV-in-TAV with an Evolut prosthesis in 2022, followed by endocarditis-related degeneration and severe restenosis. In 2024, a third prosthetic valve (Acurate neo2) was implanted using the TAV-in-TAV-in-TAV technique. With expanding indications for TAVI and increasing longevity among treated patients, complex multi-prosthesis interventions may become more frequent, highlighting the need for improved procedural planning, imaging strategies and long-term surveillance. At 1-year follow-up, the patient remains asymptomatic with preserved valve function. This case illustrates the feasibility of a third TAVI after treated prosthetic valve endocarditis, supported by CT-guided procedural planning and 1-year follow-up, which remains scarcely reported in the literature.
Keywords:
Cardiovascular medicine
Interventional cardiology
Valvar diseases
Journal
IF:
0.5
Papers:
929
Citations:
1.2W
Organization
Cited Papers